The “macro” world of microRNAs in hepatocellular carcinoma

Kaveri Sidhu†, Neetu Rohit Kapoor†, Vijaya Pandey† and Vijay Kumar*

Virology Group, International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India

MINI REVIEW ARTICLE

Published: 25 March 2015
doi: 10.3389/fonc.2015.00068

Edited by:
Rupert Langer, University of Bern, Switzerland

Reviewed by:
Francesca Fanini, Istituti di Ricovero e Cura a Carattere Scientifico, Italy
Toru Furukawa, Tokyo Women’s Medical University, Japan
*Correspondence:
Vijay Kumar, J. C. Bose Fellow, Virology Group, International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Marg, New Delhi 110067, India
e-mail: vijay@icgeb.res.in
†Kaveri Sidhu, Neetu Rohit Kapoor and Vijaya Pandey have contributed equally to this work.

INTRODUCTION

According to a WHO estimate, hepatitis B virus (HBV) and hepatitis C virus (HCV) are the major etiological agents associated with development of hepatocellular carcinoma (HCC). Progression of HCC is a multistep process that requires sequential or parallel deregulation of oncogenic and tumor suppressive pathways leading to chromosomal instability and neoplastic phenotype. In the recent years, microRNAs (miRNAs) have carved their own niche alongside oncogenes and tumor suppressors, owing to their innate ability to receive and relay multiple signals. Not surprisingly, miRNAs are fast emerging as central player in myriad of malignancies including HCC. miRNAs are reported to participate in initiation and progression of HCC, and have also been clinically correlated with risk assessment, disease grade, aggressiveness, and prognosis. Despite extensive data available on the role of miRNAs in HCC, there is a pressing need to integrate and evaluate these datasets to find its correlation, if any, with causal agents in order to devise novel interventional modalities. Through this review, we attempt to bridge the gap by consolidating the current knowledge and concepts in the field of HCC-related miRNAs with special emphasis on HBV and HCV. Further, we assess the potential of common as well as unique signatures that may be useful in developing novel biomarkers and therapeutics.

Keywords: hepatitis B virus, hepatitis C virus, hepatocellular carcinoma, microRNA, onco-miR

TRANSCRIPTIONAL REGULATION OF miRNA

The transcription of miRNA is guided by RNA polymerase (pol II) regulators, which are often deregulated in case of liver pathologies. In HBV- and HCV-associated pathogenesis, c-Myc along with viral oncoproteins modulates miRNA expression, to create an oncogenic milieu (7) facilitating the binding of transcriptional repressor complexes to miRNA promoters to allow its sustained expression (8, 9). For example, c-Myc binding to miR-122 promoter (a liver-specific TS-miR) prevents RNA pol II recruitment and H3K9 acetylation (10). c-Myc also down-regulates HNF3β, a liver-specific transcription factor, involved in transcription of miR-122. Since c-Myc itself is a target of certain miRNAs, the transcriptional control of its regulators sets on a positive feedback loop for c-Myc expression in HCC (8, 11).

c-Myc is also reported to stimulate DROSHA promoter and thus, indirectly regulate the stability of DiGeorge syndrome critical region gene 8 mRNA (12). Although c-Myc normally functions as a negative regulator of miRNAs, the levels of oncomiRs like miR-21 and miR-17-92 polycistron are elevated in c-Myc microenvironment, which down-regulate tumor suppressors (13). HCV infection per se can cause down-regulation of TS-miR-181c by promoting the recruitment of CCAAT/enhancer binding protein β (C/EBP-β) (14). In contrast, HBV positively regulates miR-181a transcription – an index of poor survival whereas it negatively regulates tumor suppressors, WiFi1 and DKK3 (controllers of Wnt signaling pathway and miR181a targets) possibly via miR181a (15–17). Inactivation of p53 in HCC leads to down-regulation of its transcriptional targets such as...
miR-34, miR-200, and miR-15/16, which allows cell proliferation and metastasis (18). p53 inactivation also alters miRNA biogenesis either by directly binding to DROSHA or via down-regulation of Dicer-1 (19), which may define miRNA target genes in HCC.

**POST-TRANSCRIPTIONAL REGULATION OF miRNA**

Hepatitis viruses often deregulate pro-proliferative pathways in HCC affecting phase-specific control of cyclins by miRNAs (6). Impairment of Dicer-1 is also frequently observed in HCC combined with tumor stemness (20). Post-transcriptional regulators of Argonaute (Argo-1 and Argo-2) such as lin-41 are over-expressed in HCC in a c-Myc dependent fashion, which down-regulates Argo protein (21). Whereas low levels of miR-99 and miR-199a induce Ago-2 expression with consequent increase in miR-21 (22, 23). Modulation of TGFβ signaling in HCC also involves miRNAs to promote tumorigenesis (24, 25). Interestingly, TGFβ effector SMAD1/5 along with RNA helicase p68 increases the maturation rate of miR-21 and miR-199 contributing to vascularization (25).

**EPIGENETIC ALTERATIONS OF miRNA**

Concordant hyper methylation of miRNA genes is frequently seen in HCC (26, 27). The master controllers of proliferation, like c-Met are epigenetically silenced by TS-miRs (28). An auto-feedback loop of hyper-methylation and gene suppression is suggested for miR-148a and miR-152 in HCC (29, 30). Acetylation status at the pri-miRNA promoters can also suppress miRNA and help relieve the suppressive effect of TS-miRs (31). Besides, sulfated glycolipids can facilitate intrahepatic metastasis (32).

HBV and HCV oncoproteins may also regulate miRNA expression (33) by engaging DNA methyltransferases (DNMT), which cause global hyper-methylation (34, 35). The HBx oncoprotein is known to sequester the epigenetic modifier PPARγ in order to down-regulate miR-122 in HCC (36). The HBx-mediated epigenetic silencing of miR-205 stabilizes HBx mRNA, and aggravates disease (37). Similarly, HCV core protein can down-regulate miR-124 and miR-345 levels by inducing DNMT expression and abrogating apoptosis (38).

**SINGLE NUCLEOTIDE POLYMORPHISM AND GENETIC ALTERATIONS**

Single nucleotide polymorphism (SNP) in the regulatory or coding regions of miRNA is essential for onco-miR expression or silencing of TS-miRs in HCC. TS-miRs such as miR-34b/c are poorly expressed in HCC owing to SNP RS4938723, which inhibits the recruitment of transcription factor GATA (39). Alternately, SNPs in the coding region of miR-196a2 and promoter of miR-106b-25 up-regulate their expression and contribute toward HCC (40, 41). SNP in the stem–loop of pre-miR-146a affects its processing efficiency and increases the risk of HCC (42). As miRNA genes are often located close to fragile sites (43), their translocation is frequently observed in many cancers. The translocation of 5’ end of the her gene (encoding miR-122) to c-myc locus can cause a massive 50-fold increase in c-Myc expression and a consequent down-regulation of miR-122 in woodchuck hepatitis virus-related HCC (24, 44).

Thus, miRNAs have emerged as crucial players in virus–host interactions, where hepatitis viruses can alter miRNA biogenesis, which in turn control key cellular pathways to establish a successful infection as discussed in the next section.

**DEREGULATION OF miRNA IN HCC**

Deregulated miRNAs play a pivotal role in supporting viral replication and perturbing key cellular processes in HBV- and HCV-associated HCC as depicted in Figure 1.

**miRNA IN THE REGULATION OF VIRAL REPLICATION**

HBV and HCV engage host miRNAs to complete virus life cycle and establish chronic infection. For example, miR-122, which is often down-regulated in many liver pathologies, shows opposing effects on HBV and HCV replication (45). miR-122 restricts HBV replication by targeting cyclin G1 and allowing p53-mediated suppression of viral genes (46). Paradoxically, miR-122 may support HBV replication by down-regulating heme oxygenase-1 (HO-1), a negative regulator of HBV transcription (47). Further, miR-1 and miR-372 along with miR-373 can enhance HBV replication by activating farnesoid X receptor-alpha (FXRA) and nuclear factor I/B, respectively (48, 49). Interestingly, miR-15b can also promote viral replication by binding to hepatocyte nuclear factor 1α and inducing HBV enhancer 1, while down-regulated miR-15b levels lower virus load and allow persistent HBV infection (50).

In case of HCV, however, binding of miR-122 to the internal ribosome entry site (IRES) in the 5‘-UTR of viral RNA augments viral replication and promotes HCV translation in an Ago-2-dependent manner (45, 51). miR-122 and miR-196 also target HO-1 by differentially regulating its repressor Bach-1 to complement or inhibit HCV replication, respectively (52, 53). Akin to miR-122, miR-199a-3p also binds to the IRES element and inhibits HCV replication (53). Interestingly, miR-27a is over-expressed in HCV cases which lowers the viral load to escape immune surveillance through a negative feedback loop (54).

**ROLE OF DEREGULATED miRNAs IN KEY CELLULAR PROCESSES**

The down-regulation of TS-miRs and concomitant elevation of onco-miRs also affect some key cellular processes, which support HCC.

**CELL CYCLE AND PROLIFERATION**

microRNAs can target cell cycle regulators to override some checkpoints and support uncontrolled proliferation. For example, TS-miR-26a targets cyclin D2/E2 that control G1/S boundary of the cell cycle since its re-expression prevented disease progression in a pre-clinical HCC model (55). Further, down-regulated levels of miR-195 and miR-138 act as tumor suppressor by targeting cyclin D1 and cyclin D3 (56, 57), while onco-miRs miR-221 and miR-222 promote tumor growth by down-regulating p27, p57, and DNA damage inducible transcript 4 (58). The let-7 family of miRNAs, which is down-regulated in HCC, allows cell proliferation by negatively regulating STAT3 and c-Myc levels and positively regulating p16INK4A (59, 60). MiR-99a suppresses G1 arrest of cancer cells by targeting cyclin D1 via mTOR (61).
SUPPRESSION OF APOPTOSIS
Cancer cells evade apoptosis by perturbing the balance between pro and anti-apoptotic factors. In aggressive HCC cases, miR-25 and miR-221 are over-expressed, which target pro-apoptotic proteins Bim and Bmf, respectively (62, 63). Down-regulated miR-29, miR-101, and miR-122 relieve suppression of their anti-apoptotic targets Bcl-2, Mcl-1, and Bcl-w, respectively, leading to increased survival in HCC (64). HBx oncoprotein down-regulates let-7 and miR-15a/16 leading to increased anti-apoptotic activity (65). Similarly, low levels of TS-miR-29c in HCC target tumor necrosis factor alpha-induced protein 3 to prevent apoptosis (66).

ALTERATION OF SIGNALING PATHWAYS
Tumor suppressor PTEN, a negative regulator of PI3K/AKT signaling is frequently targeted by elevated levels of miR-21, miR-222, and miR-29a in HCC (59, 64). miR-199-3p targets mTOR and c-Met, a HGF receptor, which controls downstream PAK4/Raf/MEK/ERK pathway (67). Restoration of miR-199-3p levels in hepatoma cells leads to G1 arrest, enhanced susceptibility to hypoxia and drug (67). HBx suppresses the p53-dependent activation of miR-148a, resulting in upregulation of AKT, ERK, and activation of mTOR pathway, which promotes tumor growth and metastasis in a HCC mouse model (68). miR-17-5p, a member of onco-miR-17-92 cluster, activates p38-MAPK- and Hsp27 pathway to promote cell migration and proliferation (69). Further, miR-222 overexpression confers metastatic potential on cancer cells by activating Akt pathway (70). Besides its pro-inflammatory role, miR-155 upregulation by HCV results in increased nuclear accumulation of signal transducer β-catenin to promote HCC (71).

EPITHELIAL–MÉSENCHYMAL TRANSITION AND METASTASIS
Prior to metastasis, tumor cells undergo epithelial–mesenchymal transition (EMT) involving loss of E-cadherin, gain of vimentin, collagen I, and fibronectin. miR-224, a highly expressed miRNA in HCC, promotes tumor growth and metastasis by silencing its target genes Cdc42, CDH1, PAK2, and BCL-2 (72). Elevated levels of miR-29a and miR-148a, which target PTEN and miR-143 also down-regulate fibronectin type III domain-containing protein 3B to enhance hepatoma cell migration (73, 74). HBx engages miR-661 and miR-373 to stimulate metastasis associated-1 protein and suppress E-cadherin, respectively (75). TS-miR-34a and miR-125b that, respectively, target c-Met and LIN28B2 oncopgenes are inversely correlated with metastasis in HCC (76, 77). In contrast, miR-200c suppresses EMT of liver cancer stem cells (CSCs) by upregulating E-cadherin, reducing vimentin, and inhibiting metastasis through repression of neurotrophic receptor tyrosine kinase 2 (78). Zeb1 and Zeb2 transcription factors are also targeted by miR-141/200c to alter E-cadherin and related gene expression involved in cell polarity (79). Not surprisingly, miR-141/200c cluster is often silenced in cancer by DNA methylation (80).

Thus, miRNAs can initiate multistep process of cancer by perturbing normal cell homeostasis and endowing cells with the ability to invade and metastasize. Further, the crosstalk between miRNAs could have a multiplier effect on their target genes as well as drug resistance cancer phenotype.
miRNAs AS DIAGNOSTIC MARKERS IN HCC

The lack of effective diagnostic methods for early HCC has rendered the overall survival rate to a low 0–14% from the time of clinical diagnosis (81). Modest precision of currently used diagnostic markers such as alpha-fetoprotein (AFP) calls for testing the prospect of miRNAs as HCC biomarkers. Circulating miRNAs are highly stable in serum owed to their resistance to RNase, extreme pH, and temperature, hence are perfect as biomarkers for detecting early stage, presymptomatic diseases such as HCC as depicted in (Figure 2).

The serum levels of miRNAs undergo alterations in HCC patients as evident from low levels of miR-16, miR-199a, and high levels of miR-21, miR-221, miR-222, miR-223, and miR-224 in serum samples (5). miR-125b is down-regulated in ~70% of primary HCC samples thus could be a good candidate for diagnosis (77). Further to expand the repertoire of prospective miRNAs in early diagnosis of HCC, down-regulated levels of TS-miR-129 in HCC can be detected in plasma samples from 85% of stage I HCC patients as compared to AFP in just 10% of stage I cases (82).

Detection of HBV- or HCV-positive HCC cases, especially those independent of cirrhosis etiology, poses a greater challenge due to lack of biomarkers. In light of this, unique expression profile of serum miRNAs in HBV- and HCV-positive HCC patients can serve as a fingerprint for distinguishing between HBV and HCV cases. Not surprisingly, miRNAs such as miR-1269, miR-224, and miR-224-3p are significantly altered specifically in HCV-associated HCCs (83). In contrast, miR-152 and miR-143 are aberrantly regulated in HBV-related HCC and hence constitute potential diagnostic markers for HBV-related HCC cases (84, 85).

Serum miRNAs enriched in exosomes can also serve as valuable non-invasive HCC biomarkers for both diagnostic and prognostic purposes. Indeed, recent findings have shown that serum exosomal miR-21 from HCC patients provides increased sensitivity of detection compared to whole serum (86). Interestingly, a report on urinary miRNAs such as miR-618 and miR-650 has opened the prospect to use them as biomarkers for early detection of HCV-induced HCC (87).

PREDICTIVE PROGNOSTIC VALUE OF miRNAs IN HCC

It is being increasingly realized that miRNAs may possess an edge over mRNA as prognostic indicators owed to their stability in clinical samples and robust expression patterns. In fact, expression profiles of a panel of 20 miRNAs can be used as metastatic predictor, correlating with survival as well as relapse rates in HCC (88). As indicated in Figure 2, hyper-methylation of miRNA promoters seems to correlate with poor prognosis, exemplified by aberrant methylation of miR-9 and corroboration with clinical outcomes (89). Further, miR-199a/b and miR-139, which are frequently down-regulated in most HCC patients, show a significant correlation with poor survival (89, 90). Likewise, low expression of miR-124 in HCC seems to be associated with more aggressive behavior and shorter survival (89). While, high levels of miR-22, miR-221, and C19MC miRNA correlate with increased risk of tumor recurrence and shorter survival (59).

Interestingly, the patterns of miRNA expression as well as SNPs in some miRNAs seem potent as predictors of patient response to various therapeutic strategies as well as disease risk (63). In Chinese and Turkish populations, a positive association has been noticed between rs11614913 (C→T) SNP in miR-196a-2 and HCC susceptibility (91, 92). Similarly, “TTCA” insertion (rs3783553) in 3′-UTR of IL-α gene, which ablates the binding site for miR-122

![FIGURE 2](https://example.com/figure2.png)
and miR-378 leading to upregulation of IL1-α, correlates well with HCC development (93).

**miRNAs IN HCC THERAPY**

Alterations in miRNA expression are frequently associated with HCC disease physiology; hence miRNAs could be used as potential druggable targets in HCC management. One of the approaches in miRNA-based HCC therapy involves using antagonism against onco-miRs. Non-human primates chronically infected with HCV when treated with locked nucleic acid (LNA) specific for miR-122 (a positive regulator of HCV replication), exhibited long-term suppression of HCV viral load, supporting therapeutic use of miRNA in HCC (2). In another pre-clinical study, involving an orthotopic HCC mouse model, oligonucleotides targeting miR-221 inhibited cell transformation and improved survival, underscoring its potential in HCC therapeutics (5). Another potential therapeutic approach for HCC treatment entails restoration of TS-miRs, thus serving as anti-cancer agents. For instance, AAV-mediated delivery of miR-122 and miR-26a and systemic restoration of miR-124 can suppress tumorigenesis in animal models of HCC. Similarly, restoration of miR-375 (2′O-methyl-modified and cholesterol conjugated form) and miR-29 could inhibit tumorigenesis in pre-clinical HCC models (2, 5).

Delivery of miRNA mimics can also be used in HCC therapy. Indeed, a cancer-targeting miRNA mimic of miR-34 (MRX34) is in phase I clinical trial performed by Mirna Therapeutics Inc., in HCC patients (5, 94). Interestingly, the mimic miRNAs are delivered using Smarticles®, which are anionic at neutral pH, but attain cationic charge in acidic tumor environment thus minimizing off-target effects (5). Importantly, the therapeutic potential of miR-122 antagonist, miravirsen was evident from a multi-centric phase IIIA trial, which showed sequestration of mature miR-122 and reduction of viral load (95).

Though miRNAs possess tremendous therapeutic potential for HCC, a major concern remains their delivery system. miRNAs can be incorporated into PEG-gylated stable nucleic acid lipid particles (SNALPS), to extend the circulation time. Further, virus-like particle (VLP) dependent delivery gives the leverage of natural tissue tropism, albeit with risk of eliciting immune response (5).

The emergence of miRNAs as novel clinical biomarkers is set to change the face of HCC diagnosis and therapeutic procedures. The proposition of miRNA profiles serving as signatures to distinguish HCV from HBV cases, though awaiting clinical evaluation, offers the advantage of accurate diagnosis and appropriate therapeutic course.

**CONCLUSION**

The heterogeneity in individual cases of cancer including HCC demands development of personalized medicine to ensure most effective treatment with minimal side effects. In such a scenario, unique tumor specific miRNA signatures, as reviewed here, will help design accurate diagnostics and therapies tailored to individual needs. The ease of delivering oligonucleotides to liver and high tolerance of normal liver cells to supplements of deficient miRNAs make HCC an ideal model to test miRNA therapy (2). Preliminary evidence in non-human primates indicates that miRNA-based treatment of chronic HCV infection provides prolonged alleviation of virus-induced liver pathology with a high barrier to viral resistance suggesting miRNAs may function as better antivirals than conventional drugs (2). CSCs, resistant to conventional chemotheraphy and cause of cancer recurrence, form the major obstacle in successful treatment of the disease. The discovery of stemness associated miRNAs in liver cancer such as miR-181, miR-150, and miR-548c-5p warrants further evaluation of their potential as druggable targets in therapies against liver CSCs (96). The gender specific discrepancy in HCC incidence can be in part explained by miRNA signatures such as higher levels of TS miR-26a and miR-26b in females that may provide them a protective edge over males (97). Elevated levels of miR-18a in HCC female patients, which suppresses protective effects of estrogen by targeting estrogen receptor-alpha, can be used as a risk predictor of HCC development in female population (98). Finally, the quest for yet elusive HBV and HCV encoded miRNAs poses a challenge, which when overcome may help in devising novel strategies to silence viral miRNA and cure liver cancer.

**REFERENCES**

1. Stewart BW, Wild CP. World Cancer Report 2014. Lyon: International Agency for Research on Cancer, World Health Organization (2014).

2. Callegari E, Gramantieri L, Domenicali M, D’Ambulo L, Sabbioni S, Negrini M. miRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches. *Cell Death Differ* (2015) 22:46–57. doi:10.1038/cdd.2014.136

3. Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. *Science* (2007) 318:1931–4. doi:10.1126/science.1149460

4. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, et al. microRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. *Proc Natl Acad Sci U S A* (2007) 104:15805–10. doi:10.1073/pnas.0707628104

5. Yang N, Ekenem NR, Sakry CA, Ray SD. Hepatocellular carcinoma and miRNAs: new perspectives on therapeutics and diagnostics. *Adv Drug Deliv Rev* (2014) 81:62–74. doi:10.1016/j.addr.2014.10.029

6. Chu R, Mo G, Duan Z, Huang M, Chang J, Li X, et al. miRNAs affect the development of hepatocellular carcinoma via dysregulation of their biogenesis and feedback loop affects hepatocarcinogenesis. *Hepatology* (2013) 57:2378–89. doi:10.1002/hep.26302

7. Bui TV, Mendell JT. Myc maestro of microRNAs. *Genes Cancer* (2010) 1:568–75. doi:10.1177/1947601910377491

8. Han H, Sun D, Li W, Shen H, Zhu Y, Li C, et al. A c-Myc-microRNA functional feedback loop affects hepatocarcinogenesis. *Hepatology* (2013) 59:2378–89. doi:10.1002/hep.26302

9. Wang L, Zhang X, Jia LT, Hu SJ, Zhao J, Yang JD, et al. c-Myc-mediated epigenetic silencing of microRNA-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma. *Hepatology* (2014) 59:1850–63. doi:10.1002/hep.26270

10. Wang B, Hu SH, Wang X, Kutay H, Bid HK, Yu J, et al. Reciprocal regulation of microRNA-122 and c-Myc in hepatocellular cancer: role of E2F1 and transcription factor dimerization partner 2. *Hepatology* (2014) 59:355–66. doi:10.1002/hep.26712

11. O’Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs module E2F1 expression. *Nature* (2005) 435:839–43. doi:10.1038/nature03677

12. Wang X, Zhao X, Gao P, Wu M. c-Myc modulates microRNA processing via the transcriptional regulation of Drosha. *Sci Rep* (2013) 3:1942. doi:10.1038/srep01942

13. Connolly E, Melegari M, Landgraf P, Tchaikovskaya T, Tennant BC, Slagle BL, et al. Elevated expression of the miR-17-92 polycistron and miR-21 in hepatadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. *Am J Pathol* (2008) 173:856–64. doi:10.2353/ajpath.2008.080096

14. Mulkerney A, Shrivastava S, Bhanja Chowdhury J, Ray R, Ray RB. Transcriptional suppression of miR-181c by hepatitis C virus enhances homeobox A1 expression. *J Virol* (2014) 88:7929–40. doi:10.1128/JVI.00787-14

---

www.frontiersin.org

March 2015 | Volume 5 | Article 68 | 5

Sidhu et al. microRNA in HCC
35. Wei X, Li Y, Cao Y, Zhang J, Jiang J, Sheng Y, et al. Up-regulated microRNA-181a induces carcinogenesis in hepatitis B virus–related hepatocellular carcinoma by targeting EZF5. BMC Cancer (2014) 14:149; doi: 10.1186/1471-2407-14-97

36. Dong YW, Wang R, Cai QQ, Qi B, Wu W, Zhang YH, et al. Sulfatide epigenetic silencing by targeting DNA methyltransferase 1. Cell Signal (2013) 25:3459–66. doi:10.1016/j.cellsig.2013.12.003

37. Zhang T, Jiang Y, Cai M, Liu F, You X, Du Y, et al. Hepatitis B virus X protein inhibits tumor suppressor miR-205 through inducing hypermethylation of miR-205 promoter to enhance carcinogenicity. Neoplasia (2013) 15:1282–91.

38. Shiu TY, Huang SM, Shih YL, Chu HC, Chang WK, Hsieh TT. Hepatitis C virus core protein down-regulates p21(Waf1/Cip1) and inhibits curcumin-induced apoptosis through microRNA-345 targeting in human hepatoma cells. PLoS One (2013) 8:e61089. doi:10.1371/journal.pone.0061089

39. Xu Y, Liu L, Liu J, Zhang Y, Zhu J, Chen J, et al. A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer (2011) 128:412–7. doi:10.1002/ijc.25342

40. Li XD, Li ZG, Song XX, Liu CF. A variant in microRNA-196a2 is associated with susceptibility to hepatocellular carcinoma in Chinese patients with cirrhosis. Pathology (2010) 42:669–73. doi:10.1016/j.pathology.2010.05.017

41. Liu Y, Yen J, Liu L, Zhai X, Liu J, et al. A genetic variant in the promoter region of miR-106b-25 cluster and risk of HBV infection and hepatocellular carcinoma. PLoS One (2012) 7:e32230. doi:10.1371/journal.pone.0032230

42. Xu T, Zhu Y, Wei QK, Yuan Y, Zhou F, Ge YY, et al. A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma. Carcinogenesis (2009) 29:2126–31. doi:10.1093/carcin/bgn195

43. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yandemuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A (2004) 101:2999–3004. doi:10.1073/pnas.030222-1204

44. Möröy T, Marchio A, Etienne J, Tóro C, Tiszlai P, Buendia MA. Rearrangement and enhanced expression of c-myc in hepatocellular carcinoma of hepatitis virus infected woodchucks. Nature (1986) 324:276–9. doi:10.1038/324276a0

45. Bandiera S, Pfeffer S, Buermier TM, Zeisel MB. MiR-122 – a key factor and therapeutic target in liver disease. J Hepatol (2014) 62:448–57. doi:10.1016/j.jhep.2014.10.004

46. Wang S, Qiu L, Yan X, Jin W, Wang Y, Chen L, et al. Loss of microRNA 122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G1–modulated P53 activity. Hepatology (2012) 55:730–41. doi:10.1002/hep.24209

47. Qiu L, Fan H, Jin W, Zhao B, Wang Y, Yu Y, et al. miR-122-induced down-regulation of HO-1 negatively affects miR-122-mediated suppression of HBV. Biochem Biophys Res Commun (2010) 398:571–7. doi:10.1016/j.bbrc.2010.07.021

48. Zhang X, Zhang E, Ma Z, Pei R, Jiang M, Schlaak JF, et al. Modulation of hepatitis B virus replication and hepatocyte differentiation by microRNA-1. Hepatology (2011) 53:476–85. doi:10.1002/hep.24195

49. Guo H, Liu H, Mitchellson K, Rao H, Luo M, Xie L, et al. microRNAs-372/373 B virus replication and hepatocyte differentiation by microRNA-1. Hepatology (2010) 51:1099–110. doi:10.1002/hep.24195

50. Dai X, Zhang W, Zhang H, Sun S, Yu H, Guo Y, et al. Modulation of HBV replication by microRNA-150 through targeting hepatocyte nuclear factor 1α. Nucleic Acids Res (2014) 42:6578–90. doi:10.1093/nar/gku260

51. Luna JM, Scheel TKH, Danino T, Shaw KS, Mele A, Fak JL, et al. Hepatitis C virus RNA functionally sequesters miR-122. Cell (2015) 160:1099–110. doi:10.1016/j.cell.2015.02.025

52. Shan Y, Zheng J, Lambrecht RW, Bonkovsky HL. Reciprocal effects of microRNA-122 on expression of heem oxygenase-1 and hepatitis C virus genes in human hepatocytes. Gastroenterology (2007) 133:1666–74. doi:10.1053/j.gastro.2007.08.002

53. Gupta P, Cairns MJ, Saksena NK. Regulation of gene expression by microRNA-122 in HCV infection and HCV-mediated hepatocellular carcinoma. Viral J (2014) 11:64. doi:10.1016/j.viralj.2014.01.004

54. Shirasuki T, Honda M, Shimakami T, Horii R, Yamasita T, Sakai Y, et al. microRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells. J Virol (2013) 87:5270–86. doi:10.1128/JVI.03022-12

55. Chen L, Zheng J, Zhang Y, Yang L, Wang J, Ni I, et al. Tumor-specific expression of microRNA-26a suppresses human hepatocellular carcinoma growth via cyclin-dependent and independent pathways. Mol Ther (2011) 19:1521–8. doi:10.1038/mi.2011.64
66. Xu T, Zhu Y, Xiong J, Ge YY, Qin Y, Zhao LJ, et al. miR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. *Carcinogenesis* (2012) 33:1113–20. doi:10.1093/carcin/bgs113
67. Jain SK, Shukla S, Sharma S, Bajpai U, Gupta K, et al. miR-133b upregulates HSP27 expression and promotes tumor invasion in hepatocellular carcinoma. *Lab Invest* (2014) 94:1675–87. doi:10.1038/121014a

68. Wang W, Zhao LI, Tan YX, Ren H, Qi ZT. MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. *Carcinogenesis* (2012) 33:1113–20. doi:10.1093/carcin/bgs113
69. Pinaud FF, Wang H, Chen YC, Chan CY, Ng SS, Li K, et al. Hsa-let-7g inhibits proliferation of hepatocellular carcinoma cells by downregulation of miR-15a/16 and upregulation of p16(INK4A). *Int J Cancer* (2011) 128:319–31. doi:10.1002/ijc.25336
70. Lan FF, Wang H, Chen YC, Chan CY, Ng SS, Li K, et al. Hsa-let-7g inhibits proliferation of hepatocellular carcinoma cells by downregulation of miR-15a/16 and upregulation of p16(INK4A). *Int J Cancer* (2011) 128:319–31. doi:10.1002/ijc.25336
71. Zhang Y, Wei W, Cheng N, Wang K, Li B, Jiang X, et al. Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling. *Hepatology* (2012) 56:1631–40. doi:10.1002/hep.24389
72. Zhang Y, Takahashi S, Tasaka A, Yoshima T, Ochi H, Chayama K. Involvement of miR-224 in cell proliferation, migration, invasion, and anti-apoptosis in hepatocellular carcinoma. *Gastroenterology* (2013) 145:2655–73. doi:10.1053/j.gastro.2013.07.023
73. Kong G, Zhang J, Zhang S, Shan C, Ye L, Zhang X. Upregulated microRNA-29a by hepatitis B virus X protein enhances hepatoma cell migration by targeting PTEN in cell culture model. *PLoS One* (2011) 6:62918. doi:10.1371/journal.pone.0062918
74. Yuan K, Lian Z, Sun B, Clayton MM, Ng IO, Feitelson MA. Role of miR-148a in hepatitis B associated hepatocellular carcinoma. *PLoS One* (2012) 7:e35331. doi:10.1371/journal.pone.0035331
75. Tian Y, Yang W, Song J, Wu Y, Ni B. Hepatitis B virus X protein-induced aberrant epigenetic modifications contributing to human hepatocellular carcinoma pathogenesis. *Mol Cell Biol* (2013) 33:2810–6. doi:10.1128/MCB.00205-13
76. Li N, Fu H, Tie Y, Hu Z, Kong W, Wu Y, et al. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. *Cancer Lett* (2009) 275:44–53. doi:10.1016/j.canlet.2008.09.035
77. Liang L, Wong CM, Ying Q, Fan DN, Huang S, Ding L et al. microRNA-125b suppressed human liver cancer cell proliferation and metastasis by directly targeting onconeogene LIN28B2. *Hepatology* (2010) 52:1731–40. doi:10.1002/hep.23904
78. Hung CH, Chiu YC, Chen CH, Hu TH. microRNAs in hepatocellular carcinoma: carcinogenesis, progression, and therapeutic target. *Biomed Res Int* (2014) 2014:486407. doi:10.1155/2014/486407
79. Park SM, Gaur AB, Lengyl E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. *Genes Dev* (2008) 22:894–907 Erratum in: *Genes Dev* (2009) 23[11]:1378. doi:10.1101/gad.164068
80. Vrab L, Jensen TJ, Garimjee AR, Groll AE, Dinckinson S, et al. Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. *PLoS One* (2010) 5:e8697. doi:10.1371/journal.pone.008697
81. A’Deane M, Faloppi L, Scartozzi M, Giampieri R, Biancomini M, Del Prete M, et al. The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment. *Molecules* (2014) 19[5]:693–406. doi:10.3390/molecules19056393
82. Lu CY, Lin KY, Tien MT, Wu CT, Uen YH, Tseng TL. Frequent DNA methylation of MiR-129-2 and its potential clinical implication in hepatocellular carcinoma. *Genes Chromosomes Cancer* (2013) 52[7]:636–43. doi:10.1002/gcc.22059
83. Hou W, Bonkovsky HL. Non-coding RNAs in hepatitis C-induced hepatocellular carcinoma: dysregulation and implications for early detection, diagnosis and therapy. *World J Gastroenterol* (2013) 19[44]:7836–45. doi:10.3748/wjg.v19.i44.7836
84. Li LM, Hu ZB, Zhou ZX, Chen X, Liu FY, Zhang F, et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. *Cancer Res* (2010) 70[23]:7978–807. doi:10.1158/0008-5472.CAN-10-1001
85. Wei Y, Cui YG, Ye P, Chen JN, Dao HY. microRNAs may solve the mystery of chronic hepatitis B virus infection. *World J Gastroenterol* (2013) 19[30]:4867–76. doi:10.3748/wjg.v19.i30.4867
86. Wang H, Hou L, Li A, Duan Y, Gao H, Song X. Expression of serum exosomal microRNA-21 in human hepatocellular carcinoma. *Biomol Res Int* (2014) 2014:864894. doi:10.1155/2014/864894
87. Abdalla MA, Haj-Ahmad Y. Promising candidate urinary microRNA biomarkers for the early detection of hepatocellular carcinoma among high-risk hepatitis C virus-infected patients. *J Cancer* (2011) 2:19–31. doi:10.7150/jca.3.19
88. Budhia A, Jia HL, Forgues M, Liu CG, Goldstein D, Lam A, et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. *Hepatology* (2008) 47[3]:987–907. doi:10.1002/hep.22160
89. Arozwar SL, Lehmann U. DNA methylation, microRNAs, and their crosstalk as potential biomarkers in hepatocellular carcinoma. *World J Gastroenterol* (2014) 20[28]:7894–93. doi:10.3748/wjg.v20.i28.7894
90. Wang C, Song B, Song W, Liu J, Sun A, Wu D, et al. Undepressed microRNA-199b-5p targets hypoxia-inducible factor-1a in hepatocellular carcinoma and predicts prognosis of hepatocellular carcinoma patients. *J Gastroenterol Hepatol* (2011) 26[11]:1630–7. doi:10.1111/j.1440-1746.2011.06758.x
91. Gao J, Jin M, Zhang M, Chen K. A genetic variant in miR-196a2 increased digestive system cancer risks: a meta-analysis of 15 case-control studies. *PLoS One* (2012) 7[1]:e30585. doi:10.1371/journal.pone.0030585
92. Akgun H, Boyram S, Beker A, Akgolli E, Ulger Y. A functional polymorphism in pre-microRNA-196a-2 contributes to the susceptibility of hepatocellular carcinoma in a Turkish population: a case-control study. *J Viral Hepat* (2011) 18[7]:e399–407. doi:10.1111/j.1365-2893.2010.01441.x
93. Gao Y, He Y, Ding Q, Wu K, Hu B, Liu Y, et al. An insertion/deletion polymorphism at miRNA-122-binding site in the interleukin-1alpha 3‘ untranslated region confers risk for hepatocellular carcinoma. *Carcinogenesis* (2009) 30[12]:2064–9. doi:10.1093/carcin/bgp238
94. Shahnaz F, Goff DW. Decoding hepatocellular carcinoma: the promise of microRNAs. *Hepatology Surg Nutr* (2014) 3[2]:93–4. doi:10.3978/j.issn.2304-3881.2014.02.08
95. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, et al. Treatment of HCV infection by targeting microRNA. *Nat Engl J Med* (2013) 368:1685–94. doi:10.1056/NEJMoa1209026

www.frontiersin.org
March 2015 | Volume 5 | Article 68 | 7

Sidhu et al. microRNA in HCC
96. Ma L, Chua MS, Andrisani O, So S. Epigenetics in hepatocellular carcinoma: an update and future therapy perspectives. World J Gastroenterol (2014) 20(2):333–45. doi:10.3748/wjg.v20.i2.333
97. Gao J, Liu QG. The role of miR-26 in tumors and normal tissues (Review). Oncol Lett (2011) 2(6):1019–23.
98. Liu WH, Yeh SH, Lu CC, Yu SL, Chen HY, Lin CY, et al. microRNA-18a prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells. Gastroenterology (2009) 136(2):683–93. doi:10.1053/j.gastro.2008.10.029

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 01 February 2015; accepted: 08 March 2015; published online: 25 March 2015.

Citation: Sidhu K, Kapoor NR, Pandey V and Kumar V (2015) The “macro” world of microRNAs in hepatocellular carcinoma. Front. Oncol. 5:68. doi: 10.3389/fonc.2015.00068

This article was submitted to Gastrointestinal Cancers, a section of the journal Frontiers in Oncology.
Copyright © 2015 Sidhu, Kapoor, Pandey and Kumar. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.